John Paul Christodouleas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
John Paul Christodouleas has a total of 125 co-authors. Here are the top co-authors by number of shared publications:
- Brian C. Baumann
Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri
7 shared publications S. Bruce Malkowicz
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
4 shared publications- Curtiland Deville
Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
3 shared publications Neha Vapiwala
Department of Radiation Oncology at the University of Pennsylvania, Philadelphia, PA
3 shared publicationsThomas J. Guzzo
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
3 shared publicationsAmit Bahl
University Hospitals Bristol NHS Foundation Trust, Bristol, UK
2 shared publications
Latest Publications
- 23 June 2025
- Published by Oxford University Press (OUP) in British Journal of Radiology
Optimizing lymph node metastasis imaging in MR-guided radiotherapy for oligometastatic prostate cancer
MR-guided radiotherapy (MRgRT) using MRI integrated linear accelerator (MR-LINAC) is a critical advancement in prostate cancer (PC) treatment. Leveraging the superior soft tissue contrast of MR imaging (MRI), along with online adaptation capabilities and real-time MRI for advanced motion management, MRgRT has demonstrated efficacy in localized PC irradiation. Recent studies have demonstrated that MRgRT can effectively treat individual lymph node metastasis (LNM), with preliminary results showing excellent patient tolerability and safety as a novel metastasis-directed radiotherapy for oligometastatic PC (omPC). However, current LNM imaging on an MR-LINAC is limited and suboptimal, creating reliance on diagnostic MRI and positron emission tomography (PET) for differentiation, registration, contouring, and adaptation. The inherent uncertainty and errors within these processes impair the accuracy and precision of LNM irradiation in MRgRT. This review aims to provide an overview of the current imaging techniques employed in clinical MRgRT practice for omPC, highlighting the unmet clinical needs due to the limitations of LNM imaging using an MR-LINAC. Furthermore, it reviews promising advanced LNM MRI techniques potentially transferable to MR-LINAC. Lastly, it discusses future developments in LNM imaging on an MR-LINAC and its potential as a comprehensive one-stop imaging solution for future omPC MRgRT.
- 23 June 2025
- Published by Oxford University Press (OUP) in British Journal of Radiology
Optimizing lymph node metastasis imaging in MR-guided radiotherapy for oligometastatic prostate cancer
MR-guided radiotherapy (MRgRT) using MRI integrated linear accelerator (MR-LINAC) is a critical advancement in prostate cancer (PC) treatment. Leveraging the superior soft tissue contrast of MR imaging (MRI), along with online adaptation capabilities and real-time MRI for advanced motion management, MRgRT has demonstrated efficacy in localized PC irradiation. Recent studies have demonstrated that MRgRT can effectively treat individual lymph node metastasis (LNM), with preliminary results showing excellent patient tolerability and safety as a novel metastasis-directed radiotherapy for oligometastatic PC (omPC). However, current LNM imaging on an MR-LINAC is limited and suboptimal, creating reliance on diagnostic MRI and positron emission tomography (PET) for differentiation, registration, contouring, and adaptation. The inherent uncertainty and errors within these processes impair the accuracy and precision of LNM irradiation in MRgRT. This review aims to provide an overview of the current imaging techniques employed in clinical MRgRT practice for omPC, highlighting the unmet clinical needs due to the limitations of LNM imaging using an MR-LINAC. Furthermore, it reviews promising advanced LNM MRI techniques potentially transferable to MR-LINAC. Lastly, it discusses future developments in LNM imaging on an MR-LINAC and its potential as a comprehensive one-stop imaging solution for future omPC MRgRT.
- Open Access
- 3 March 2025
- Published by Springer Nature
- Vol. 15273, 1-35
Overview of the Head and Neck Tumor Segmentation for Magnetic Resonance Guided Applications (HNTS-MRG) 2024 Challenge
Magnetic resonance (MR)-guided radiation therapy (RT) is enhancing head and neck cancer (HNC) treatment through superior soft tissue contrast and longitudinal imaging capabilities. However, manual tumor segmentation remains a significant challenge, spurring interest in artificial intelligence (AI)-driven automation. To accelerate innovation in this field, we present the Head and Neck Tumor Segmentation for MR-Guided Applications (HNTS-MRG) 2024 Challenge, a satellite event of the 27th International Conference on Medical Image Computing and Computer Assisted Intervention. This challenge addresses the scarcity of large, publicly available AI-ready adaptive RT datasets in HNC and explores the potential of incorporating multi-timepoint data to enhance RT auto-segmentation performance. Participants tackled two HNC segmentation tasks: automatic delineation of primary gross tumor volume (GTVp) and gross metastatic regional lymph nodes (GTVn) on pre-RT (Task 1) and mid-RT (Task 2) T2-weighted scans. The challenge provided 150 HNC cases for training and 50 for final testing hosted on grand-challenge.org using a Docker submission framework. In total, 19 independent teams from across the world qualified by submitting both their algorithms and corresponding papers, resulting in 18 submissions for Task 1 and 15 submissions for Task 2. Evaluation using the mean aggregated Dice Similarity Coefficient showed top-performing AI methods achieved scores of 0.825 in Task 1 and 0.733 in Task 2. These results surpassed clinician interobserver variability benchmarks, marking significant strides in automated tumor segmentation for MR-guided RT applications in HNC.
- 3 March 2025
- Published by Springer Nature
- Vol. 15273, 1-35
Open AccessOverview of the Head and Neck Tumor Segmentation for Magnetic Resonance Guided Applications (HNTS-MRG) 2024 Challenge
Magnetic resonance (MR)-guided radiation therapy (RT) is enhancing head and neck cancer (HNC) treatment through superior soft tissue contrast and longitudinal imaging capabilities. However, manual tumor segmentation remains a significant challenge, spurring interest in artificial intelligence (AI)-driven automation. To accelerate innovation in this field, we present the Head and Neck Tumor Segmentation for MR-Guided Applications (HNTS-MRG) 2024 Challenge, a satellite event of the 27th International Conference on Medical Image Computing and Computer Assisted Intervention. This challenge addresses the scarcity of large, publicly available AI-ready adaptive RT datasets in HNC and explores the potential of incorporating multi-timepoint data to enhance RT auto-segmentation performance. Participants tackled two HNC segmentation tasks: automatic delineation of primary gross tumor volume (GTVp) and gross metastatic regional lymph nodes (GTVn) on pre-RT (Task 1) and mid-RT (Task 2) T2-weighted scans. The challenge provided 150 HNC cases for training and 50 for final testing hosted on grand-challenge.org using a Docker submission framework. In total, 19 independent teams from across the world qualified by submitting both their algorithms and corresponding papers, resulting in 18 submissions for Task 1 and 15 submissions for Task 2. Evaluation using the mean aggregated Dice Similarity Coefficient showed top-performing AI methods achieved scores of 0.825 in Task 1 and 0.733 in Task 2. These results surpassed clinician interobserver variability benchmarks, marking significant strides in automated tumor segmentation for MR-guided RT applications in HNC.
- 1 November 2020
- Published by Elsevier in Practical Radiation Oncology
- Vol. 10 (6) , 389-401
A Multidisciplinary Consensus Recommendation on a Synoptic Radiation Treatment Summary: A Commission on Cancer Workgroup Report
- 1 November 2020
- Published by Elsevier in Practical Radiation Oncology
- Vol. 10 (6) , 389-401
A Multidisciplinary Consensus Recommendation on a Synoptic Radiation Treatment Summary: A Commission on Cancer Workgroup Report
- 20 February 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (6_suppl) , 336
External validation and optimization of international consensus clinical target volumes for adjuvant radiation in bladder cancer.
336 Background: International Consensus (IC) clinical target volumes (CTVs) have been proposed to standardize radiation field design in the treatment of patients at high risk for local regional failure (LRF) after radical cystectomy. The purpose of this study was to externally validate the IC CTVs in a cohort of post-surgical patients followed for LRF, and identify revisions that might improve its performance. Methods: Of 334 patients with pT3-4 bladder cancer treated with radical cystectomy, 58 (17%) developed LRF, of which 52 had CTs available for review. Images with LRF were exported into a treatment planning system, and IC CTVs were contoured and evaluated for adequacy of coverage of each LRF, with respect to both the patient and each of six pelvic subsites: common iliac (CI), obturator region (OR), external and internal iliac (EI/II), presacral (PS), cystectomy bed (CB), or other pelvic site. Revisions to the IC contours were proposed based on the findings. Results: Of the 52 patients with documented LRF, 13 (25%) patients had LRFs that were outside of the IC CTV involving 17 pelvic subsites: 5 near the CI CTV, 5 near the OR CTV, 1 near the EI/II, and 6 near the CB. The 5 CI failures were located superior to the CTV and the 5 OR failures were located medial to the CTV. Increasing the superior boundary of the CI to a vessel-based definition of the aortic bifurcation, and increasing the medial extension of the OR by an additional 9 mm, decreased the rate of patients with LRF outside of the IC CTV to 7 (13%) patients. Conclusions: “Modified IC CTVs” inclusive of a slight adjustment superiorly for the common iliac region, and medially for the obturator region, may reduce the risk for pelvic failure in patients treated with adjuvant radiation therapy.
- 20 February 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (6_suppl) , 336
External validation and optimization of international consensus clinical target volumes for adjuvant radiation in bladder cancer.
336 Background: International Consensus (IC) clinical target volumes (CTVs) have been proposed to standardize radiation field design in the treatment of patients at high risk for local regional failure (LRF) after radical cystectomy. The purpose of this study was to externally validate the IC CTVs in a cohort of post-surgical patients followed for LRF, and identify revisions that might improve its performance. Methods: Of 334 patients with pT3-4 bladder cancer treated with radical cystectomy, 58 (17%) developed LRF, of which 52 had CTs available for review. Images with LRF were exported into a treatment planning system, and IC CTVs were contoured and evaluated for adequacy of coverage of each LRF, with respect to both the patient and each of six pelvic subsites: common iliac (CI), obturator region (OR), external and internal iliac (EI/II), presacral (PS), cystectomy bed (CB), or other pelvic site. Revisions to the IC contours were proposed based on the findings. Results: Of the 52 patients with documented LRF, 13 (25%) patients had LRFs that were outside of the IC CTV involving 17 pelvic subsites: 5 near the CI CTV, 5 near the OR CTV, 1 near the EI/II, and 6 near the CB. The 5 CI failures were located superior to the CTV and the 5 OR failures were located medial to the CTV. Increasing the superior boundary of the CI to a vessel-based definition of the aortic bifurcation, and increasing the medial extension of the OR by an additional 9 mm, decreased the rate of patients with LRF outside of the IC CTV to 7 (13%) patients. Conclusions: “Modified IC CTVs” inclusive of a slight adjustment superiorly for the common iliac region, and medially for the obturator region, may reduce the risk for pelvic failure in patients treated with adjuvant radiation therapy.
- Open Access
- 27 January 2017
- Published by SAGE Publications in Bladder Cancer
- Vol. 3 (1) , 19-30
The Rationale for Post-Operative Radiation in Localized Bladder Cancer
Local-regional recurrence for patients with ≥pT3 disease after radical cystectomy is a significant problem. Chemotherapy has not been shown to reduce the risk of local-regional recurrences in randomized prospective trials, and salvage therapies for l
- 27 January 2017
- Published by SAGE Publications in Bladder Cancer
- Vol. 3 (1) , 19-30
Open AccessThe Rationale for Post-Operative Radiation in Localized Bladder Cancer
Local-regional recurrence for patients with ≥pT3 disease after radical cystectomy is a significant problem. Chemotherapy has not been shown to reduce the risk of local-regional recurrences in randomized prospective trials, and salvage therapies for l
- Open Access
- 17 January 2017
- Published by Springer Nature in Radiation Oncology
- Vol. 12 (1) , 19
The use of dose-escalated radiation for locally advanced non-small cell lung cancer in the U.S., 2004–2013
The clinical effects of radiation dose-intensification in locally advanced non-small cell lung (NSCLCa) and other cancers are challenging to predict and are ideally studied in randomized trials. The purpose of this study was to assess the use of dose-escalated radiation for locally advanced NSCLCa in the U.S., 2004–2013, a period in which there were no published level 1 studies on dose-escalation. We performed analyses on two cancer registry databases with complementary strengths and weaknesses: the National Oncology Data Alliance (NODA) 2004–2013 and the National Cancer Database (NCDB) 2004–2012. We classified locally advanced patients according to the use of dose-escalation (>70 Gy). We used adjusted logistic regression to assess the association of year of treatment with dose-escalated radiation use in two periods representing time before and after the closure of a cooperative group trial (RTOG 0617) on dose-escalation: 2004–2010 and 2010–2013. To determine the year in which a significant change in dose could have been detected had dose been prospectively monitored within the NODA network, we compared the average annual radiation dose per year with the forecasted dose (average of the prior 3 years) adjusted for patient age and comorbidities. Within both the NODA and NCDB, use of dose-escalation increased from 2004 to 2010 (p < 0.0001) and decreased from 2010 to 2013 (p = 0.0018), even after controlling for potential confounders. Had the NODA network been monitoring radiation dose in this cohort, significant changes in average annual dose would have been detected at the end of 2008 and 2012. Patterns of radiation dosing in locally advanced NSCLCa changed in the U.S. in the absence of level 1 evidence. Monitoring radiation dose is feasible using an existing national cancer registry data collection infrastructure.
- 17 January 2017
- Published by Springer Nature in Radiation Oncology
- Vol. 12 (1) , 19
Open AccessThe use of dose-escalated radiation for locally advanced non-small cell lung cancer in the U.S., 2004–2013
The clinical effects of radiation dose-intensification in locally advanced non-small cell lung (NSCLCa) and other cancers are challenging to predict and are ideally studied in randomized trials. The purpose of this study was to assess the use of dose-escalated radiation for locally advanced NSCLCa in the U.S., 2004–2013, a period in which there were no published level 1 studies on dose-escalation. We performed analyses on two cancer registry databases with complementary strengths and weaknesses: the National Oncology Data Alliance (NODA) 2004–2013 and the National Cancer Database (NCDB) 2004–2012. We classified locally advanced patients according to the use of dose-escalation (>70 Gy). We used adjusted logistic regression to assess the association of year of treatment with dose-escalated radiation use in two periods representing time before and after the closure of a cooperative group trial (RTOG 0617) on dose-escalation: 2004–2010 and 2010–2013. To determine the year in which a significant change in dose could have been detected had dose been prospectively monitored within the NODA network, we compared the average annual radiation dose per year with the forecasted dose (average of the prior 3 years) adjusted for patient age and comorbidities. Within both the NODA and NCDB, use of dose-escalation increased from 2004 to 2010 (p < 0.0001) and decreased from 2010 to 2013 (p = 0.0018), even after controlling for potential confounders. Had the NODA network been monitoring radiation dose in this cohort, significant changes in average annual dose would have been detected at the end of 2008 and 2012. Patterns of radiation dosing in locally advanced NSCLCa changed in the U.S. in the absence of level 1 evidence. Monitoring radiation dose is feasible using an existing national cancer registry data collection infrastructure.
- Open Access
- 1 October 2016
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 96 (2) , S186
Phase I Trial of Everolimus in Combination with Salvage Radiation Therapy (RT) for Post-prostatectomy Biochemical Recurrence (BCR) in Prostate Cancer (PC) Patients
- 1 October 2016
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 96 (2) , S186
Open AccessPhase I Trial of Everolimus in Combination with Salvage Radiation Therapy (RT) for Post-prostatectomy Biochemical Recurrence (BCR) in Prostate Cancer (PC) Patients
- 1 April 2016
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 94 (5) , 1040-1042
Adjuvant Radiation for Locally Advanced Bladder Cancer? A Question Worth Asking
- 1 April 2016
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 94 (5) , 1040-1042
Adjuvant Radiation for Locally Advanced Bladder Cancer? A Question Worth Asking
- 23 January 2016
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 95 (2) , 703-706
Validating a Local Failure Risk Stratification for Use in Prospective Studies of Adjuvant Radiation Therapy for Bladder Cancer
- 23 January 2016
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 95 (2) , 703-706
Validating a Local Failure Risk Stratification for Use in Prospective Studies of Adjuvant Radiation Therapy for Bladder Cancer